Drug intelligence / Profile preview

d-penicillamine + hydroxychloroquine

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

A combination of d-penicillamine and hydroxychloroquine that has been studied for the treatment of rheumatoid arthritis. Clinical trials have shown that this combination is not superior to d-penicillamine alone for progressive rheumatoid arthritis, and therefore cannot be recommended. The combination may increase the effects of either medication.

Beyond the preview

Go deeper on d-penicillamine + hydroxychloroquine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on d-penicillamine + hydroxychloroquine.

Explore the full profile